PARP inhibitors: Treating mCRPC from a genetic basis
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
PSMA-PET imaging product, Gozellix, launches on US market
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
Phase 2 trial of oncolytic immunotherapy launches in BCG-unresponsive NMIBC
FDA accepts new drug application for zoliflodacin for uncomplicated gonorrhea